THE ‘ART’ OF WOMEN’S HEALTH – Add back or not add back? Obseva: Both options good as UF, endo trials…
Month: March 2017
ObsEva SA to Attend Needham Annual Healthcare Conference in NYC
Geneva, Switzerland – 24 March 2017 – ObsEva SA (Nasdaq: OBSV), a Swiss biopharmaceutical company focused on the development and commercialization of novel therapeutics for…
Both OTR Antagonists, Atosiban and Nolasiban, Inhibits PGE2/PGF2α-Induced Contractions of Human Pregnant Myometrium In Vitro
Sung Hye Kim, Hauwa Ahmed, Lucia Riaposova, Oliver Pohl, Andre Chollet, Aylin Hanyaloglu, Phillip R Bennett, Vasso Terzidou
SRI Conference, 15-18 March 2017, Orlando, FL
Abstract S-031: Page 245A
Scientific Abstracts Reproductive Sciences Vol. 24 (1_suppl), 1A-51A, March 2017
ObsEva to Present Pharmacology Results Demonstrating OBE022 Exerts a Synergistic Effect in Combination with Standard of Care in Animal Model for Preterm Labor
– OBE022 is ObsEva’s potential first-in-class, oral and selective PGF2alpha receptor antagonist – Geneva, Switzerland – 17 March 2017 – ObsEva SA (Nasdaq: OBSV), a Swiss biopharmaceutical company…
ObsEva Starts Phase 3 Clinical Program for Nolasiban in ART
– IMPLANT2 study to confirm efficacy and safety of novel, oral oxytocin receptor antagonist in infertile patients undergoing embryo transfer…